Related by context. All words. (Click for frequent words.) 68 seronegative 66 coinfected 65 HIV seropositive 64 seropositive 63 antiretroviral naïve 63 castrate resistant 63 seropositivity 63 virus HBV 62 NRTI resistance 62 e antigen HBeAg 61 HIV coinfected 61 genotype 1b 61 CC genotype 60 BRAF V#E 60 nonnucleoside reverse transcriptase inhibitors 60 seroconverted 60 nonmetastatic 60 HBeAg positive 60 essential thrombocythemia ET 60 HIV HCV coinfected 60 AZT 3TC 60 euthyroid 59 HBeAg negative 59 BRAF V#E mutation 59 LHRH receptor positive 59 clade B 59 K#N 59 ErbB2 positive 59 Endometrial 59 pT2 59 ritonavir boosted 58 coinfected patients 58 nucleoside analog 58 syngeneic 58 HIV uninfected 58 Pharmacokinetics PK 58 ELISPOT 58 treatment naïve genotype 58 log# copies mL 58 HIV seronegative 58 indinavir 58 prostate cancer CaP 58 immunodeficient 58 abacavir lamivudine 58 Syndrome HARS 58 completely resected 58 prostate carcinoma 58 HIV RNA 57 hepatocellular carcinomas 57 Chronic Hepatitis C 57 invasive carcinomas 57 lamivudine resistant 57 PBMCs 57 HBsAg positive 57 Flu Cy 57 lymphocytosis 57 CCR5 antagonist 57 HIV coinfection 57 AZT zidovudine Retrovir 57 Protease inhibitor 57 #mg ATC 57 novel VDA molecule 57 virus HCV infection 57 HLA DQ2 57 antiretroviral naive 57 HepC 57 relapsed ALL 57 Pneumocystis carinii pneumonia 57 relapsed MM 57 Leukemias 57 acid phosphatase PAP 57 BCG vaccinated 57 chronic HBV 57 promoter methylation 57 surgically resected 57 progesterone receptor negative 57 K ras mutations 57 tenofovir Viread 57 pT3 57 sero positive 57 Selective Inhibitor 56 demonstrated antitumor activity 56 HBsAg 56 SSc 56 Amplicor 56 Raltegravir 56 Telbivudine 56 undetectable HBV DNA 56 Recombinant interferon alpha 56 rs# [001] 56 coinfection 56 ug dose 56 Phase 2b Clinical Trial 56 chronic HCV 56 Retroviral 56 investigational integrase inhibitor 56 papillary renal cell carcinoma 56 mutated K ras 56 PEG IFN 56 HCV Genotype 56 HCV antibody 56 efavirenz EFV 56 Cytotoxic T 56 genotypic resistance 56 null responder 56 Saquinavir 56 protease inhibitor PI 56 3TC lamivudine Epivir 56 Trichomonas vaginalis 56 tipranavir ritonavir 56 overt hypothyroidism 56 HCV genotype 56 trichomonas 56 Serum concentrations 56 median CD4 56 Viread tenofovir disoproxil fumarate 56 recurrent epithelial ovarian 56 BARACLUDE ® 56 transcriptase inhibitors NNRTIs 56 viremic 55 genital ulcer 55 peripheral blood mononuclear 55 nucleoside analogue 55 antibody titer 55 C#Y 55 virus HCV 55 IL#B 55 tissue transglutaminase 55 Stage IIB 55 PENNVAX ™ B 55 inhibit replication 55 HBeAg negative patients 55 Virologic 55 stage IIIb IV 55 Hepatitis C Virus 55 Relapsed Refractory 55 TT genotype 55 gene polymorphism 55 antiandrogen 55 HCV replicon 55 BRCA1 BRCA2 55 Immunohistochemical staining 55 K#R [002] 55 achieved sustained virological 55 HCV infected 55 serologically 55 SNP rs# [001] 55 underwent surgical resection 55 T1c 55 perinatally 55 nevirapine Viramune 55 resistant hormone refractory 55 Screening Assay 55 NNRTI resistant virus 55 CYT# potent vascular disrupting 55 nucleotide analogue 55 abacavir Ziagen 55 Genotypes 55 tenofovir FTC 55 gastric adenocarcinoma 55 Combination REOLYSIN R 55 CCR5 delta# 55 Apolipoprotein B 55 tryptase 55 Lipodystrophy 55 treatment naive genotype 55 invasive lobular 55 PROSTVAC VF 55 recurrent genital herpes 55 ovarian carcinoma 55 immunostaining 55 hepatoma 55 epithelial tumors 55 hypermethylated 55 recurrent metastatic 55 Tipranavir 55 cells uL 55 mitoxantrone chemotherapy 55 TLR7 agonist 55 replicon 55 abnormal cytology 55 HBeAg 54 FOLFOX6 54 HLA DR2 54 Adjuvant Treatment 54 HER2 expression 54 cytologically confirmed 54 tumors GIST 54 Virus HIV 54 TTR gene 54 immunocompetent 54 tenofovir emtricitabine 54 Etravirine 54 efavirenz Sustiva 54 colon carcinoma 54 NRTI 54 Circumcised men 54 CCR5 receptor antagonist 54 -#.# log# copies mL 54 anti HBs 54 Epigenomics proprietary 54 Adenomas 54 lupus anticoagulant 54 TDF FTC 54 serologic 54 bladder ovarian 54 CIN2 + 54 pyrazinamide 54 stavudine d4T 54 NNRTI resistance 54 ano genital warts 54 amprenavir 54 Infected Patients 54 ASCUS 54 combination antiretroviral therapy 54 surgically resectable 54 chronic HCV genotype 54 CD# + [001] 54 bronchoalveolar lavage fluid 54 gastric carcinoma 54 Stage IIIb 54 tipranavir r 54 Immunohistochemical analysis 54 Chlamydia trachomatis infection 54 Selzentry TM 54 Isentress raltegravir 54 nevirapine NVP 54 metastatic malignant 54 HIV1 54 enteroviral 54 heparanase 54 Naive Patients 54 virologically 54 HER2/neu 54 adiponectin concentrations 54 naive HCV 54 Histologic 54 polytherapy 54 NRTI backbone 54 Pegylated Interferon 54 H pylori 54 relapsing remitting MS RRMS 54 thrombopoietin TPO natural 54 biochemical relapse 54 lactate dehydrogenase LDH 54 genital ulcers 54 sleeping sickness trypanosomiasis 54 Sustiva efavirenz 54 HPV-#/# 54 Clusterin 54 immunoglobulin G 54 HCV SPRINT 54 leukemia ALL 54 p# antigen 54 hormone receptor negative 53 leiomyomas 53 hypogonadal 53 undergone radical prostatectomy 53 #:#-# [031] 53 N. gonorrhoeae 53 nucleotide analog 53 HLA DRB1 * 53 GSTP1 53 genital secretions 53 Multiple Myeloma MM 53 mIU ml 53 Serologic 53 HCV genotype 1 53 resected pancreatic cancer 53 GG genotype 53 Ribavirin causes 53 hepatitis C HCV 53 heavily pretreated 53 colorectal carcinoma 53 transiently transfected 53 MKC# MT 53 DermaVir Patch 53 transcriptase inhibitor NNRTI 53 IgG antibody 53 hepatitis C genotype 53 trastuzumab Herceptin ® 53 CYP#A# CYP#D# 53 lymphomas leukemias 53 apolipoprotein B 53 decompensated liver disease 53 antigen PSA levels 53 haematologic 53 mRCC 53 glucuronide 53 nelfinavir 53 RRM1 53 enfuvirtide 53 RhD negative 53 ovarian endometrial 53 Papillary 53 poly ICLC 53 circulating endothelial cells 53 compound AEZS 53 HCV RESPOND 2 53 pyrimethamine 53 nucleoside analogues 53 Preclinical Study 53 MAGE A3 53 chronic HBV infection 53 cEVR 53 chlamydial 53 NMIBC 53 Opportunistic infections 53 virologic response EVR 53 MAGE A3 ASCI 53 diabetes mellitus DM 53 KRAS wild 53 HIV serostatus 53 protease inhibitors PIs 53 heterosexually acquired 53 histologic subtype 53 rs# [004] 53 trastuzumab Herceptin R 53 Peginterferon 53 Disease Progression 53 specific antigen PSA 53 cisplatin resistant 53 Ph + acute lymphoblastic 53 metastatic renal cell 53 HLA DR4 immune 53 Vaccine Adjuvant 53 ABCB1 53 CCR5 tropic 53 P. ovale 53 visceral metastases 53 adalimumab Humira 53 inhibin B 53 T#I [002] 53 interleukin IL -# 53 Her2/neu 53 Factor Receptor 53 receiving antiretroviral therapy 53 Viral Load 53 ribavirin RBV 53 KRAS oncogene 53 rilpivirine 53 p# biomarker 53 serum concentrations 53 plasma pharmacokinetics 53 hemagglutinin H 53 TMC# [002] 53 elevated LDH 53 impaired glucose metabolism 53 breast carcinoma 53 naïve HCV 53 p#HER# positive 53 SIV infected 53 untreated metastatic melanoma 53 Fibroblast 52 KRAS mutation 52 Respiratory Syncytial Virus RSV 52 undetectable viral loads 52 ERBB2 52 Tyrosine Kinase Inhibitor 52 Cancer Res 52 SGPT 52 aciclovir 52 IFN gamma 52 undetectable hepatitis C 52 taxane therapy 52 Treatment Naive HIV 52 genital ulcer disease 52 transcriptase inhibitors 52 hemagglutination inhibition HAI 52 bladder carcinoma 52 Vaccine Protects Against 52 subtyped 52 TPV r 52 Plasma concentrations 52 zidovudine AZT 52 pegylated interferon alpha 52 pregnancy bacterial vaginosis 52 virologically suppressed 52 BRCA2 carriers 52 CCR5 tropic HIV 52 heterozygotes 52 valacyclovir 52 Kinoid 52 accumulate preferentially 52 J Am Coll 52 piperacillin tazobactam 52 LH FSH 52 investigational protease inhibitor 52 binds selectively 52 Hepsera adefovir dipivoxil 52 lopinavir 52 Autoantibodies 52 experienced virologic failure 52 fructosamine 52 Cervista HPV HR 52 immunohistochemical analysis 52 pg ml 52 thyroid carcinoma 52 genotyped 52 Viread Emtriva 52 hemagglutination inhibition 52 Human immunodeficiency virus 52 log# reduction 52 RNA copies mL 52 Mouse Model 52 KRAS mutations occur 52 transgenic rats 52 cells μL 52 nodal metastasis 52 serum antibody 52 LEXIVA r 52 Relapsed Refractory Multiple Myeloma 52 μmol L 52 HSV2 52 cytokeratin 52 Leydig cell 52 underwent resection 52 Circumcision reduces 52 lymphocyte counts 52 null responder HCV 52 HIV seroconversion 52 CDKN2A 52 Genotypic 52 rectal gonorrhea 52 #:#-# [023] 52 lung ovary 52 bronchoalveolar lavage BAL 52 STELARA ® 52 Homozygous 52 seroconversion 52 HER2 homodimer levels 52 Vaxfectin formulated 52 baseline LDH 52 anagrelide 52 5 HT2A serotonin 52 Epstein Barr virus EBV 52 co trimoxazole 52 constitutively expressed 52 HepG2 cells 52 polyglutamate 52 pancreatic prostate 52 dapagliflozin plus 52 PDGFRA 52 baseline neutrophil counts 52 HCV genotypes 52 nasal colonization 52 ovarian pancreatic 52 operable breast cancer 52 hepatic lipase 52 HBeAg seroconversion 52 simian foamy virus 52 Histological 52 % CI #.#-#.# [003] 52 normal karyotype 52 III EGFRvIII 52 leukaemias 52 elevated ALT 52 refractory chronic lymphocytic 52 parasitaemia 52 antibody titers 52 Upregulation 52 RASSF1A 52 Salmonella Shigella 52 liver histology 51 hematological parameters 51 mucinous 51 MLH1 51 sustained virological response 51 NPM1 mutations 51 alpha 2a 51 M#V mutation 51 TNFalpha 51 chlamydial infection 51 ERalpha 51 Immunohistochemical 51 CROI 51 quinacrine 51 pretransplant 51 doxorubicin cyclophosphamide 51 Prostate Lung Colorectal 51 lamivudine refractory patients 51 hematopoietic cancers 51 HBV DNA 51 Familial Hypercholesterolemia 51 Histopathologic 51 fluvastatin 51 atazanavir sulfate 51 carcinoembryonic antigen 51 Shows Promise Against 51 Vaginal gel 51 KRAS mutations 51 eosinophilic asthma 51 Prezista darunavir 51 Polymorphisms 51 DAS# CRP 51 Ki# 51 K RAS 51 IgM 51 HBV genotype 51 nmol liter 51 proband 51 lipohypertrophy 51 CRp 51 UGT#A# * 51 initiating antiretroviral therapy 51 liver metastasis 51 pretreatment serum 51 Hemodialysis Patients 51 Highly Active 51 #mg BID [001] 51 #S rRNA gene 51 unprotected receptive anal 51 viral titers 51 hepatitis B infection 51 Rapid Virologic Response 51 thyroid peroxidase 51 thyroglobulin 51 BRAF mutation 51 cervical lesions 51 basal cell nevus syndrome 51 alanine aminotransferase ALT 51 Natalizumab 51 transthyretin TTR 51 non mutated KRAS 51 gonococcal infections 51 darunavir 51 monocyte chemotactic protein 51 Estrogen Receptor 51 rubella hepatitis 51 missense mutations 51 hepatorenal syndrome 51 atazanavir Reyataz 51 aged ≥ 51 Cathepsin B 51 VIRAMUNE R 51 Darunavir 51 S/GSK# 51 Presents Positive 51 cyclophosphamide methotrexate 51 S. suis 51 #mg QD [002] 51 CD8 responses 51 lamivudine zidovudine 51 medically inoperable 51 adjuvant cisplatin 51 NNRTI 51 TRAIL R1 51 aminotransferase 51 NSABP B 51 saquinavir 51 inhibitor RG# 51 Aptivus ® 51 HER-2/neu 51 agonistic human 51 seroprotection 51 paclitaxel cisplatin 51 Modulates 51 dose cohort 51 FLT3 mutations 51 lopinavir r 51 homogenates 51 steroidogenic 51 follicular fluid 51 clinico pathological 51 breast pancreatic 51 miR #a [001] 51 CD# CD# 51 Sustained Virologic Response 51 assay detects 51 XL# administered orally 51 CIN3 51 REYATAZ r arm 51 Clade B 51 humanized therapeutic 51 Testis 51 Gag Pol 51 lactate dehydrogenase 51 idiopathic membranous nephropathy 51 prostate adenocarcinoma 51 serum prostate 51 administered subcutaneously 51 virological response 51 FLT3 ITD 51 pmol L 51 bFGF 51 IFN α 51 advanced adenomas 51 CD3 + 51 #p# [003] 51 Subtypes 51 HCV infections 51 osteosarcomas 51 fluconazole resistant 51 unresectable tumors 51 undetectable viral 51 ritonavir boosted lopinavir 51 Antigen Specific 51 efavirenz emtricitabine 51 symptomatic BPH 51 superinfection 51 maternal serum 51 TMPRSS2 ERG 51 ritonavir boosted protease inhibitor 51 Prognostic significance 51 hepatitis B virus HBV 51 poor metabolizers 51 parasitemia 51 Peg IFN 51 Renal Cell Carcinoma 51 FTC TDF 51 serum albumin 51 d4T stavudine Zerit 51 H#K#me# 51 de novo kidney transplant 51 triggers apoptosis programmed 51 PCR assay 51 nucleoside naive 51 nonobese 51 REYATAZ R 51 HER2 HER2 51 seroprevalence 50 naive HCV genotype 50 reproductive tract infections 50 HLA DRB1 50 T1a 50 Atypical Hemolytic Uremic Syndrome 50 atypical hyperplasia 50 alkylating 50 Shows Promising 50 chronic HCV infection 50 darunavir ritonavir 50 mg RDEA# 50 serum HBV DNA 50 Sexually active 50 infliximab monotherapy 50 LungAlert TM 50 postexposure prophylaxis 50 chlamydial infections 50 heFH 50 unprotected vaginal 50 immunohistochemistry IHC 50 baseline CD4 50 null responders 50 Septin9 50 alanine aminotransferase 50 serum lipid levels 50 % CI #.#-#.# [008] 50 creatinine ratio 50 viral kinetics 50 noncarriers 50 PCA3 gene 50 tenofovir DF 50 Prostate specific antigen 50 titers 50 elvitegravir 50 FUSILEV enhances 50 mRNA expression 50 TOP2A 50 Hepatitis B virus 50 lymphoproliferative disorders 50 herpes zoster shingles 50 TIMP 1 50 invasive ductal 50 viraemia 50 VivaGel TM 50 HLA DR 50 saquinavir ritonavir 50 μg liter 50 variant allele 50 dopamine D2 50 -#.# log# 50 plasma lipid 50 galiximab 50 TMC# r 50 Alkaline Phosphatase 50 bendamustine ifosfamide 50 interferon ribavirin 50 Epivir 50 bioavailable testosterone 50 HBeAg positive patients 50 unmethylated 50 triglyceride concentrations 50 Kaposi Sarcoma 50 viral tropism 50 CD8 + lymphocytes 50 Helicobacter pylori H. pylori 50 suppress viral replication 50 ribavirin therapy 50 IGF binding 50 prednisone prednisolone plus 50 homozygotes 50 rapid virologic response 50 CD4 lymphocyte count 50 REYATAZ r 50 haematological 50 N Engl J 50 aplastic anemia AA 50 Completes Dosing 50 serum ALT 50 Patients Receiving 50 progesterone receptors 50 suppressive therapy 50 ertapenem 50 relapsed ovarian cancer 50 immunoreactive 50 HER2 ErbB2 50 dacarbazine DTIC 50 Azacitidine 50 Cytogenetic 50 siRNA conjugates 50 potent antiretroviral therapy 50 μg L 50 Prognostic factors 50 uterine cervix 50 copies ml 50 clinically evaluable 50 % Confidence Interval 50 viral loads 50 Kaposi sarcoma 50 mL/min/#.# m 2 50 MYH9 gene 50 pegIFN 50 boosted atazanavir 50 atazanavir 50 clodronate 50 NNRTIs 50 sulphadoxine pyrimethamine 50 SLITRK1 50 HER2 amplified 50 neutrophil counts 50 VKORC1 50 virologic failures 50 ritonavir Norvir 50 Protease inhibitors 50 adefovir 50 genotype 50 achieved CCyR 50 BRCA1 mutation carriers 50 immunocytochemistry 50 urate oxidase 50 Predict Response 50 nasopharyngeal specimens 50 XL# inhibits 50 siRNAs targeting 50 HCV 50 ALT normalization 50 rFSH 50 receptive anal sex 50 advanced neoplasia 50 alfa 2a 50 causative mutations 50 HAART regimens 50 zidovudine lamivudine 50 castration resistant hormone refractory 50 SensoLyte ™ 50 EDEMA3 trial 50 BRAF gene mutations 50 #rd Annual CTRC 50 whose tumors overexpress 50 boosted protease inhibitor 50 neutralizing antibody responses 50 #:#-# [029] 50 tumor histology 50 potent suppressor 50 inhibitor COX 50 ZNF# 50 unmutated 49 endometrial ovarian 49 Nelfinavir 49 undetectable virus HCV 49 Aspergillus nidulans 49 hepatic fibrosis 49 CYP#D# genotype 49 sarcomatoid 49 HBV 49 promoter hypermethylation 49 undetectable viral load 49 melanoma ovarian 49 immunosuppressed patients 49 candidemia 49 TIMP 49 HIVMA promotes quality 49 estrogen receptor ER 49 detectable HCV RNA 49 siRNA knockdown 49 homocysteine concentrations 49 atazanavir ritonavir 49 colorectal adenocarcinoma 49 lipid lowering medications 49 hyaluronidase enzyme 49 nasopharyngeal swabs 49 leukocytosis 49 neutralizing antibody 49 RT PCR assay 49 anal HPV 49 vitro pharmacology 49 achieved ACR# 49 Histopathological 49 lung carcinomas 49 prostate cancer CRPC 49 mg kg Hematide 49 underwent liver transplantation 49 serum urate levels 49 Prednisone Against Refractory 49 estrogen receptor beta agonist 49 SCIg 49 radical prostatectomy RP 49 HBV vaccine 49 latent tuberculosis infection 49 chronic Hepatitis B 49 echocardiographic parameters 49 Ultrasensitive 49 raltegravir 49 MDS MPD 49 serostatus 49 immunohistochemical staining 49 oral FTY# 49 PRNP 49 CCR5 inhibitor 49 HER2 neu 49 C#T [002] 49 RECORD1 49 SPINK1 49 bacteraemia 49 extracapsular extension 49 latently infected 49 cause cardiac channelopathies 49 Renal Cell Carcinoma RCC 49 Kivexa 49 uncomplicated falciparum malaria 49 HIV Infection 49 cTnI 49 valganciclovir 49 attain statistical significance 49 SIV infection 49 TM PCA3 49 darunavir r 49 Vidaza ® 49 Merck Isentress 49 abnormal lipid 49 confidence interval #.#-#.# 49 aminotransferase levels 49 cytomegalovirus infection 49 mammalian tissues 49 nondiabetic 49 Traficet EN 49 HCV antibodies 49 clinicopathologic 49 bone marrow reticulin deposition 49 obstructive coronary artery 49 miRNA expression 49 endometrial breast 49 microsatellite instability 49 peginterferon alfa 2b 49 cell acute lymphoblastic 49 Randomized Phase II 49 deCODE ProstateCancer TM 49 systolic dysfunction 49 Viral load 49 gastrin analogue TT 49 5 FU leucovorin 49 P. falciparum malaria 49 #mg BID [003] 49 causes genital herpes 49 essential thrombocythemia 49 PSA nadir 49 response CCyR 49 LTBI 49 bezafibrate 49 sequence homology 49 urine cytology 49 mcg BID 49 invasive lobular carcinoma 49 overactive bladder OAB 49 retrospective cohort 49 irinotecan doxorubicin oxaliplatin paclitaxel 49 elevated triglyceride levels 49 Gag polymorphisms 49 mmol l 49 poliovirus vaccine 49 Randomised Trial 49 nonpsychotic 49 cisplatin gemcitabine 49 ceftriaxone 49 Score TOS 49 sustained virologic response 49 differentially expressed 49 statistical significance p 49 autoantibody levels 49 fosamprenavir 49 baseline serum creatinine 49 advanced adenoma 49 ALT elevation 49 locoregional recurrence 49 reactogenicity 49 intact parathyroid hormone 49 Test Detects 49 antiangiogenic therapy 49 IGFBP 49 CANCIDAS 49 seropositive patients 49 acquired immunodeficiency syndrome 49 cTnT 49 bacterial vaginosis BV 49 transdermal estradiol 49 extensively metabolized 49 mg kg dose 49 virologic responses 49 PCR RFLP 49 APOC3 49 familial aggregation 49 poly ADP ribose polymerase 49 PegIFN RBV 49 MIC# [001] 49 Cloretazine 49 serum biomarkers 49 eosinophil count 49 Hepatocytes 49 immuno suppressed 49 placental malaria 49 #.#ng/ml 49 severe neutropenia 49 aneuploid 49 Haptoglobin 49 HLA B 49 diagnosed GBM 49 reaction RT PCR 49 pancreatic carcinoma 49 Western blotting 49 immunoreactivity 49 LDL cholesterol HDL cholesterol 49 HBV infections 49 follicular Non Hodgkin 49 IU ml 49 pCR 49 mIU mL 49 renal cell carcinomas 49 transgene expression 49 exomes 49 preferentially bind 49 pg mL 49 uncircumcised males 49 Ep CAM 49 ductal carcinomas 49 plasma renin activity 49 IPAH 49 SensoLyte 49 pneumocystis pneumonia 49 CR nPR 48 MGd 48 IgG antibodies 48 #nd EORTC NCI 48 metaplasia 48 tests miRview TM 48 smoldering multiple myeloma 48 nanomolar 48 T1DM 48 kaempferol 48 non porcine pancreatic 48 NHANES III 48 epoetin alpha 48 CD4 + cells 48 rhGH 48 Multicenter AIDS 48 DAS# remission 48 antibody titres 48 MCSP respectively 48 vWF 48 low dose ritonavir 48 receiving INTRON 48 CMV retinitis 48 RAF kinase VEGFR 48 Gastrointestinal Stromal Tumors 48 breast carcinomas 48 rs# rs# 48 Basal Cell 48 hamartomas 48 situ LCIS 48 CD4 + cell 48 iPTH 48 Lopinavir 48 colorectal gastric 48 urothelial 48 aspartate aminotransferase 48 â ‰ ¥ 48 maraviroc 48 retrospectively analyzed 48 PTPN# 48 aminotransferase ALT 48 allogeneic HSCT 48 CRP concentrations 48 #ng/ml 48 chronic hepatitis B. 48 gene amplification 48 genital herpes infections 48 lymphoblastoid cell lines 48 pancreatic adenocarcinoma 48 #mg dose [002] 48 PREZISTA ritonavir